Pathology: mNSCLC - L1 - all population; mNSCLC - L1 - PDL1 positive; mNSCLC - L2 - PDL1 negative;
| mNSCLC - L1 - all population | mNSCLC - L1 - PDL1 positive | mNSCLC - L2 - PDL1 negative | ||
| MYSTIC (DT ; all population), 2020 | MYSTIC (DT ; PDL1>25%), 2020 | ARCTIC (DT ; study B ; PDL1<25%), 2020 | ||
| durvalumab plus tremelimumab | 3 | T1 | T1 | T1 |
| Standard of Care (SoC) | 0 | T0 | T0 | T0 |